Literature DB >> 25515751

Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.

Javier Klett, Jake Reeves, Nils Oberhauser, Lucia Pérez-Regidor, Sonsoles Martín-Santamaria1.   

Abstract

Toll-like receptors (TLRs) are a family of proteins with a key role in the innate immune system. They are specialized in the recognition of molecular patterns present in microbial components, through mechanisms not yet unraveled at atomic level. Improvement in the understanding of the molecular mechanisms that drive TLR signaling is of paramount importance to grasp key aspects of immunity, potentially leading to the design of new molecules able to modulate their functions. Toll-like receptor 4 (TLR4), along with its accessory protein myeloid differentiation factor 2 (MD-2), builds a heterodimeric complex that specifically recognizes lipopolysaccharides (LPS), which are present on the cell wall of gramnegative bacteria, activating the immune response. Some TLR4 modulators are undergoing preclinical and clinical evaluation for the treatment of sepsis, inflammatory diseases, cancer, and rheumatoid arthritis. Reported X-ray crystal structures together with molecular modeling studies, not reviewed before in the literature, have recently contributed to the elucidation of key interactions at atomic level of the binding between the TLR4/MD-2 system and different TLR4/MD-2 ligands. The purpose of this review is to summarize these reported studies which may account for the SAR rationalization of natural/ synthetic agonist/antagonist TLR4 binders and may also guide further design of novel TLR4 modulators.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25515751     DOI: 10.2174/1568026614666141215144831

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  7 in total

1.  Activation of Human Toll-like Receptor 4 (TLR4)·Myeloid Differentiation Factor 2 (MD-2) by Hypoacylated Lipopolysaccharide from a Clinical Isolate of Burkholderia cenocepacia.

Authors:  Flaviana Di Lorenzo; Łukasz Kubik; Alja Oblak; Nicola Ivan Lorè; Cristina Cigana; Rosa Lanzetta; Michelangelo Parrilli; Mohamad A Hamad; Anthony De Soyza; Alba Silipo; Roman Jerala; Alessandra Bragonzi; Miguel A Valvano; Sonsoles Martín-Santamaría; Antonio Molinaro
Journal:  J Biol Chem       Date:  2015-07-09       Impact factor: 5.157

2.  Piperidylmethyloxychalcone improves immune-mediated acute liver failure via inhibiting TAK1 activity.

Authors:  Sun Hong Park; Jeong-Ah Kwak; Sang-Hun Jung; Byeongwoo Ahn; Won-Jea Cho; Cheong-Yong Yun; Chang Seon Na; Bang Yeon Hwang; Jin Tae Hong; Sang-Bae Han; Youngsoo Kim
Journal:  Exp Mol Med       Date:  2017-11-17       Impact factor: 8.718

3.  Brucella Lipopolysaccharide and pathogenicity: The core of the matter.

Authors:  Judith A Smith
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882

4.  Full-Atom Model of the Agonist LPS-Bound Toll-like Receptor 4 Dimer in a Membrane Environment.

Authors:  Alejandra Matamoros-Recio; Juan Felipe Franco-Gonzalez; Lucia Perez-Regidor; Jean-Marc Billod; Joan Guzman-Caldentey; Sonsoles Martin-Santamaria
Journal:  Chemistry       Date:  2021-10-12       Impact factor: 5.236

Review 5.  Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators.

Authors:  Lucía Pérez-Regidor; Malik Zarioh; Laura Ortega; Sonsoles Martín-Santamaría
Journal:  Int J Mol Sci       Date:  2016-09-09       Impact factor: 5.923

Review 6.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.

Authors:  Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri
Journal:  Vaccines (Basel)       Date:  2017-10-04

7.  Identification of a Heme Activation Site on the MD-2/TLR4 Complex.

Authors:  John D Belcher; Ping Zhang; Julia Nguyen; Zachary M Kiser; Karl A Nath; Jianjun Hu; John O Trent; Gregory M Vercellotti
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.